Stay always up-to-date
with our corporate news

News Archive

2014

Ypsomed is expanding to China

The Ypsomed Group is well-positioned in the burgeoning Chinese diabetes market. With its newly founded subsidiary in Beijing, Ypsomed is investing in the future.

Ypsomed Demonstrates Its Commitment on World Diabetes Day

The Ypsomed Group, the leading developer and manufacturer of injection systems for self-medication and a diabetes specialist with global activities, is promoting public awareness of diabetes by conducting internal and external campaigns at each of its sites.

Ypsomed semi-annual results 2014/15: Report and press release

Ypsomed is emphatically forging ahead on the path of continued growth.

Ypsomed and Terumo Corporation agree on collaboration

Terumo Corporation a Japanese global operating medical technology group plans to supplement its range of products and services towards the pharmaceutical industry and integrate its prefillable polymer syringe PLAJEX™ into Ypsomed's autoinjector YpsoMate®. The first pharma customer has already placed an order for this new offering, with further customers expected.

Ypsomed newly supplies AstraZeneca with the Bydureon Pen

Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon Pen, based on Ypsomed's LyoTwist® platform.

Ypsomed increases dividends to shareholders by 50%

Annual general meeting of July 1, 2014.

Ypsomed Strengthens Sales in Its Business Segments

Injection Systems and Diabetes Care to be managed separately.

Ypsomed 2013/14 business year: Report and press release

Ypsomed successfully implements turnaround strategy and signs three new Injection Systems contracts with GlaxoSmithKline (GSK), Palatin Technologies, Inc. and Pharmstandard.

Change in Ypsomed leadership

Simon Michel elected as successor of CEO Willy Michel.

Ypsomed achieves retail business turnaround and increases operating profit significantly

Preliminary information regarding the annual financial statement 2013/14.

Ypsomed Is Expanding to Italy

Presence in the third largest diabetes market in Europe with the unique tubeless insulin pump mylife OmniPod.